The 2025 Tokyo Bio-Pharma (hereinafter referred to as the Japan Bio-Expo) will be held in Tokyo from July 9 to 11. The organizer of the exhibition is Reed Exhibitions Japan, and the in-PHARMA JAPAN and the Tokyo Bio-Pharma will also be held at the same time.
Bio-Pharma Japan is the largest biopharmaceutical technology exhibition in Japan. It covers R&D technology, manufacturing technology and contract services. Visitors, exhibitors and people related to biopharmaceutical technology from all over the world.
Audience sectors: 43% Pharmaceutical companies: mainly from R&D, production and facilities, quality control and other departments 30% Cosmetics companies 16% Detergent companies 11% Import and export companies/distributors
The main exhibitors of the last session: Watson, Merck, Lonza, Cytiva, Sony, Kaneka, Mitsubishi Chemical, Panasonic, Hitachi, Siemens, GEA PHARMA, Hitachi
In recent years, with the growing trend of Japan’s aging population, the market demand for related industries in the country has also increased year by year. At the same time, the Japanese government is actively carrying out a policy of innovation in the pharmaceutical market, which requires strong support from the international market and the introduction of new technologies and resources, especially in the development of new drug testing, the standardized practical application of stem cell regenerative medicine and cell therapy, and the safety technology of testing new drugs.
Since Japan opened its pharmaceutical market, multinational pharmaceutical companies have actively entered the Japanese pharmaceutical market. From the perspective of pharmaceutical companies, on the one hand, foreign companies have entered the Japanese pharmaceutical market, and on the other hand, Japanese pharmaceutical companies are undergoing mergers and reorganizations, such as Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Dainippon Pharmaceutical and Sumitomo Pharma, Daiichi Pharmaceutical and Sankyo Pharmaceutical. Pharmaceutical companies with foreign backgrounds have developed markets in Japan, and the speed of entry and growth is very fast. Japan is the world’s second largest pharmaceutical raw material market, accounting for 15% of the world’s total prescription drug market. The scale of investment in the research and development of the pharmaceutical and biotechnology industries ranks second in the world. And the global biopharmaceutical industry is developing rapidly.